Category: Pharmaceuticals

Bayer files prostate cancer drug darolutamide with Japanese regulators

Bayer files prostate cancer drug darolutamide with Japanese regulators Bayer hopes to sway drug prescribers and for darolutamide to surpass the billion-euro annual sales milestone on approval. Bayer, the German multinational pharmaceutical company recently announced that it has filed darolutamide, its prostate cancer drug, with the Japanese regulators. It is …

Novo Nordisk confirms positive results for Ozempic in Type 2 diabetes

Novo Nordisk, the Demark-based diabetes care giant, has recently published positive results for a 30 week trial to evaluate the safety and efficacy of Ozempic (semaglutide) 1.0mg in combination with SGLT-2 inhibitor (SGLT-2i) treatment. The SUSTAIN 9 Phase IIIb study was reportedly performed in adults having Type 2 diabetes, who …

Japan’s AGC acquires Malgrat Pharma Chemicals to expand into Europe

Malgrat’s production lines are designed to handle the diverse scales needed, from pharmaceutical development phase to commercialization stage Japanese manufacturing firm AGC Inc., has recently announced that the company has completed the acquisition of Malgrat Pharma Chemicals (MPC), S.L.U, a Spain based synthetic pharmaceutical active ingredient producer. Apparently, the financial …

Sanofi & Regeneron Pharmaceuticals announce results for Dupixent study

Dupixent showed significant improvement in patients with acute chronic rhinosinusitis with nasal polyps as well as co-morbid asthma. A recently released report for Phase 3 trials of Dupixent has conclusively demonstrated that dupilumab in combination with corticosteroid nasal spray has the potential to improve chronic sinus disease. Besides this, the …

Novartis to pursue development of therapy for elevated Lipoprotein(a)

The company would be licensing the rights to develop as well as commercialize TQJ230 for targeted cardiovascular therapy If approved, the TQJ230 would be a first in class therapy specifically designed for elevated Lp(a) Novartis International AG (Novartis), a renowned Swiss pharmaceutical firm, has reportedly announced that it has decided …

Bausch Health acquires rights for preservative-free allergy eye drop

The EM-100 developed by Eton Pharmaceuticals would be the first ever preservative-free eye drop available in U.S. that can be used in allergic ocular itching. Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc, along with its parent company and Eton …

Split-dosing of DARZALEX initial infusion approved by U.S. FDA

The safety profile of DARZALEX was unchanged in case of a split or single initial dose and there were no safety events in case of the split-dosage regimen. The Janssen Pharmaceutica recently announced that it has received approval from the U.S. Food and Drug Administration for split-dosage regimen of DARZALEX®(daratumumab). …

Eli Lilly launches Olumiant in India, forays into autoimmune segment

The U.S. based pharmaceutical firm Eli Lilly and Company has reportedly announced to have forayed in the autoimmune segment in India. As per trusted sources, the drug maker has launched a new once-daily oral therapy, named as Olumiant, to treat rheumatoid arthritis. Reportedly, OlumiantTM is an advanced and effective once-daily …

Cannabis firm MedMen acquires PharmaCann worth USD 682 million

Los Angeles-based cannabis firm, MedMen Enterprises Inc. has recently announced its binding letter of intent to acquire the Illinois-based medical cannabis provider PharmaCann LLC for a valuation of USD 682 million. With thus takeover, MedMen will be expanding its reach with 79 licensed cannabis facilities amid growing operations in 12 …

CVS and Aetna’s megamerger worth $69 billion wins DOJ approval

U.S. retail drugstore chain, CVS Health Corp. has recently won approval of a $69 billion acquisition of healthcare insurer Aetna, Inc. by the U.S. Department of Justice (DOJ), paving the way for a merger that can cut health care costs for consumers. Sources close to the matter suggest merger of …